轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02575 轩竹生物-B

未开盘 08-03 16:08:10

11.580

+0.590

+5.37%

最高11.630	最低10.920	成交量49.45万
今开10.990	昨收10.990	日振幅6.46%
总市值59.98亿	流通市值59.98亿	总股本5.18亿
成交额558.73万	换手率0.10%	流通股本5.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":11.58,"timestamp":1785744490359,"preClose":10.99,"halted":0,"volume":494453,"delay":0,"changeRate":0.05368516833484985,"floatShares":517947790,"shares":518000000,"eps":-0.615094774650428,"marketStatus":"未开盘","change":0.59,"latestTime":"08-03 16:08:10","open":10.99,"high":11.63,"low":10.92,"amount":5587284,"amplitude":0.064604,"askPrice":11.58,"askSize":5000,"bidPrice":11.39,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.6092919937574993,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785807000000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":10.99,"openAndCloseTimeList":[[1785720600000,1785729600000],[1785733200000,1785744000000]],"volumeRatio":1.745826566413622,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575","defaultTab":"news","newsList":[{"id":"2654071005","title":"【券商聚焦】中邮证券首予轩竹生物（02575）买入评级 指商业化前景获看好","url":"https://stock-news.laohu8.com/highlight/detail?id=2654071005","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654071005?lang=zh_cn&edition=full","pubTime":"2026-07-28 15:40","pubTimestamp":1785224415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，轩竹生物-B 新一代PPI抑制剂安奈拉唑钠肠溶片用于成人反流性食管炎的NDA申请已获NMPA受理，该适应症国内患者基数约4000万，临床需求庞大。其首发适应症已纳入医保，目前覆盖近3000家医疗终端，较前代PPI抑制剂具备临床优势，较P-CAB类具备价格和安全性优势，商业化前景获看好。基于公司商业化产品逐渐放量、在研管线丰富，首次覆盖，给予“买入”评级。风险提示包括产品销售、新药临床进度及数据不及预期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","161027","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653240080","title":"轩竹生物(02575)续跌6% 涉与合作企业技术转让纠纷 仲裁赔付933万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653240080","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653240080?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:39","pubTimestamp":1784601589,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物(02575)低位震荡，报11.14元，跌5.99%，成交额177.6万元。消息面上，轩竹生物披露仲裁结果，公司与合作生物技术企业因 2021 年药品技术转让合同产生纠纷，对方曾将特定药品国内上市、商业化独家权益转让给轩竹生物，后续该品类仿制药纳入国家集采，同类药品价格大幅下行，叠加研发成果、GMP 核查进度分歧，双方协商合同免责终止无果。合作方 2024 年向中国国际经济贸易仲裁委员会提交仲裁申请，诉求确认合同终止并索要经济赔偿。仲裁庭于 7 月 15 日出具终局裁决，裁定轩竹生物合计支付约 933 万元人民币，该裁决具备终局法律约束力。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986365","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652726461","title":"板块热度升温、估值逻辑重塑，轩竹生物-B（2575.HK）商业化放量箭在弦上","url":"https://stock-news.laohu8.com/highlight/detail?id=2652726461","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652726461?lang=zh_cn&edition=full","pubTime":"2026-07-20 12:19","pubTimestamp":1784521195,"startTime":"0","endTime":"0","summary":"轩竹生物当前业务层面的关键变量正在加速落地，恰处于这一价值重估的节点上。","market":"fut","thumbnail":"https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/7.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5642242","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144933555","title":"轩竹生物-B：仲裁裁决需支付约人民币9.33百万元 已于2025年计提拨备","url":"https://stock-news.laohu8.com/highlight/detail?id=1144933555","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144933555?lang=zh_cn&edition=full","pubTime":"2026-07-19 18:51","pubTimestamp":1784458260,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司7月19日发布自愿公告称，公司已收到中国国际经济贸易仲裁委员会于2026年7月15日作出的终局裁决，裁定公司需向一名合作方支付约人民币9.33百万元。该裁决现已生效并具约束力。2021年5月21日，轩竹生物与该合作方签署技术转让合同，后者将特定药品在中国获批上市及商业化销售的独家权利转让予轩竹生物。轩竹生物表示，针对本次仲裁可能产生的9.33百万元支付责任，公司已在2025年度财务报表中计提会计拨备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107629304","title":"轩竹生物-B 6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1107629304","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107629304?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:46","pubTimestamp":1783413962,"startTime":"0","endTime":"0","summary":"2026年7月7日，轩竹生物科技股份有限公司披露截至2026年6月30日止月份的证券变动月报表。报告显示，轩竹生物-B报告期内已发行普通股（H股）数量为517,947,790股，注册股本为人民币517,947,790元，环比无变化，库藏股份数量也保持为零。轩竹生物-B方面表示，董事会确认严格遵守香港联交所《上市规则》以及相关法律法规，确保公司公众持股比例符合上市要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647582361","title":"轩竹生物-B：1类创新药安奈拉唑钠肠溶片新适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2647582361","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647582361?lang=zh_cn&edition=full","pubTime":"2026-06-30 13:24","pubTimestamp":1782797040,"startTime":"0","endTime":"0","summary":"6月30日，轩竹生物-B（02575）发布公告，宣布自主研发的国家1类创新药安奈拉唑钠肠溶片（商品名：安久卫?）用于治疗成人反流性食管炎的新适应症上市申请已获国家药品监督管理局正式受理。此次受理基于在中国开展的多中心、随机、双盲双模拟、阳性药平行对照的III期注册临床研究结果，安奈拉唑钠60mg组治愈率为88.4%，而雷贝拉唑钠20mg组为84.6%，两组率差为3.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788166360.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788166360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","BK1161","159992","BK1191","02575","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143369709","title":"轩竹生物-B：安纳拉唑钠III期试验达主要终点，愈合率达88.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143369709","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143369709?lang=zh_cn&edition=full","pubTime":"2026-06-30 12:07","pubTimestamp":1782792437,"startTime":"0","endTime":"0","summary":"轩竹生物制药股份有限公司宣布，其核心产品安纳拉唑钠的III期临床试验已达到主要疗效终点。数据显示，该药物在治疗相关适应症时，展现出高达88.4%的愈合率，这一积极结果为后续的新药上市申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645501420","title":"港股公告掘金 | 真健康医疗、江西生物等4家公司启动招股 卓越睿新与阿里云签署全面深度合作框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2645501420","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645501420?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:55","pubTimestamp":1782089756,"startTime":"0","endTime":"0","summary":"【重大事项】“穿刺手术机器人第一股”真健康医疗(02697) 6月22日起招股 发售价119.3至135.4港元江西生物(06915)6月22日至6月25日招股 拟全球发售3623.45万股H股来福谐波(03952)6月22日至6月25日招股 拟全球发售1344.19万股H股鲟龙科技(06715)6月22日至6月25日招股 拟全球发售1633.29万股H股卓越睿新(02687)与阿里云计算有限公司","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1154","002352","BK1235","LU1152091168.USD","LU1807302812.USD","BK1216","06887","01250","BK1558","03952","LU1023057109.AUD","LU0359202008.SGD","BK1116","02657","LU0359201612.USD","BK1560","00697","LU0067412154.USD","LU1008478684.HKD","300750","02697","BK1207","BK1610","02575","LU1152091754.HKD","06715","LU1993786604.SGD","LU0359201885.HKD","01798","LU0880133367.SGD","06936","BK1554","02687","BK1191","BK1151","SCGEY","03750","BK1594","LU1960683339.HKD","06915","LU2213484517.USD","02558","BK1228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645097981","title":"轩竹生物-B(02575)：安奈拉唑钠新适应症根除幽门螺杆菌之III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2645097981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645097981?lang=zh_cn&edition=full","pubTime":"2026-06-21 18:11","pubTimestamp":1782036715,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，团自主研发的创新药安奈拉唑钠肠溶片用于含安奈拉唑钠的铋剂四联疗法根除幽门螺杆菌之III期临床研究，近日已成功完成首例患者入组，标志着该项关键注册临床研究正式迈入实质性执行阶段。本次Hp根除适应症III期临床研究于2026年4月获中国国家药品监督管理局药品审评中心批准开展后，迅速完成首例患者入组，充分彰显公司临床开发团队的高效执行能力，亦标志该项目正式进入临床执行关键阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","III","BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644199702","title":"轩竹生物-B(02575)：岳鑫获选举职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2644199702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644199702?lang=zh_cn&edition=full","pubTime":"2026-06-18 18:24","pubTimestamp":1781778296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，公司职工代表大会已于2026年6月18日举行，会上岳鑫女士经出席会议的职工代表审议后获选举为第二届董事会职工代表董事，自2026年6月18日起生效，任期与第二届董事会任期相同。任期届满后，彼可膺选连任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181690563","title":"轩竹生物-B5月股份变动月报：H股数量增至517,947,790股","url":"https://stock-news.laohu8.com/highlight/detail?id=1181690563","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181690563?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:01","pubTimestamp":1780570871,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2026年6月4日发布的最新股份变动月报显示，截至2026年5月31日，公司已发行H股数量由上月底的160,701,996股增加至517,947,790股，股本总额相应变动为人民币517,947,790元。同时，公司未上市股份由357,245,794股减至0股。根据公告，股份数量变化主要源于357,245,794股未上市股份转换为同等数量的H股，该部分H股已自2026年5月13日起在香港联合交易所有限公司上市。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640213206","title":"港股异动 | 轩竹生物-B(02575)涨超5% 公司3款核心品种已经进入商业化阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2640213206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640213206?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:42","pubTimestamp":1780555365,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B涨超5%，截至发稿，涨5.17%，报17.29港元，成交额4683.53万港元。消息面上，国海证券近期研报指出，预计公司收入会随着商业化进程的加速持续增长。安奈拉唑十二指肠溃疡适应症已上市，根除幽门螺杆菌、反流性食管炎的适应症处于拓展中。此外，核心产品已经出海。2026年4月公司就吡洛西利和地罗阿克与Boston Oncology CGT签订中东及北非区域的许可及供货协议，公司获得首付款、可能超过1亿美元的里程碑付款、销售分成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02575","BK4585","VXUS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640013255","title":"轩竹生物-B(02575)午后涨逾7% 机构料收入随商业化进程加速持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2640013255","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640013255?lang=zh_cn&edition=full","pubTime":"2026-06-04 14:05","pubTimestamp":1780553108,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物-B 午后涨幅扩大，最新报17.63港元，涨幅7.3%，成交额4156.14万港元。消息面上，国海证券研究表示，公司3款核心品种已经进入商业化阶段。安奈拉唑十二指肠溃疡适应症已上市，根除幽门螺杆菌、反流性食管炎的适应症处于拓展中。该机构预计公司2026/2027/2028年收入分别为2.21/4.91/7.14亿元，同比增长326.58%/122.17%/45.52%；归母净利润分别为-2.02/-1.08/1.01亿元，对应PS估值34.8/15.6/10.8倍，并预料公司收入会随着商业化进程的加速持续增长，首次覆盖，给予“增持”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983071","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175784295","title":"轩竹生物-B拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1175784295","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175784295?lang=zh_cn&edition=full","pubTime":"2026-05-27 16:56","pubTimestamp":1779872169,"startTime":"0","endTime":"0","summary":"轩竹生物-B近日公告，董事会建议向股东大会申请一般性授权，以回购不超过于批准当日已发行H股总数10%的股份。股东周年大会定于2026年6月18日召开，若议案获通过，公司可根据实际经营与资金状况，在法律法规与上市规则允许的情况下，通过内部资金及合法来源实施回购。董事会强调，此回购授权的实施取决于市场情况、资金安排及公司财务状况等多种因素，只有在其认为符合公司及股东整体最佳利益的情形下才会进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01384","02526","01300","01396","02670","06938","00400","02575","BK1171","02411","01333","LU0307460666.USD","02889","02623","02228","00650","00363","LU0287142896.SGD","00826","LU0314109678.HKD","02565","BK1155","01378","02706","06090","02655","06651","02142","BK1100","02659","HK0001040143.USD","06636","08299","VXUS","02685","02650","00305","02675","03858","03881","09696","02652","03317","06682","00290","01907","01021","02729","02726","06051"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635760402","title":"轩竹生物(02575)跌7.60% 全流通落地叠加估值偏高下挫股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2635760402","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635760402?lang=zh_cn&edition=full","pubTime":"2026-05-14 14:04","pubTimestamp":1778738649,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物(02575)股价持续承压，一度创历史新低。现报18.37元，跌7.6%，成交量82万。消息面上，5月13日，3.57亿股非上市股份转为H股上市，公司实现100%全流通，H股总数增至5.18亿股，流通盘显著扩大。从基本面来看，公司 2025 年实现营收 5177.2 万元，同比增长 72%，营收端保持较高增速，但归母净亏损达 2.46 亿元，尚未实现盈利。叠加当前市销率（TTM）高达 219.58 倍，估值处于高位区间，在流通盘扩大、盈利尚未兑现的背景下，市场估值消化压力凸显，进一步压制股价表现。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981376","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149723312","title":"轩竹生物科技股份有限公司完成357,245,794股非上市股份转换H股，已发行股本增至517,947,790股","url":"https://stock-news.laohu8.com/highlight/detail?id=1149723312","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149723312?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:56","pubTimestamp":1778583400,"startTime":"0","endTime":"0","summary":"2026年5月12日，轩竹生物科技股份有限公司（“公司”，股票代码：02575，股票名称：轩竹生物-B）发布公告，披露已将357,245,794股非上市股份转换为同等数量的H股，约占本次变动前公司已发行股本的68.97%。该等转换后，新增H股将于2026年5月13日起在香港联合交易所有限公司上市，公司H股总数由160,701,996股增至517,947,790股，库存股份数维持为0。\n公司在公告中指出，上述股份转换已获得董事会正式授权，并按照香港联交所证券上市规则及相关法律规定办理。公告由联席公司秘书何成明签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"轩竹生物科技股份有限公司完成357,245,794股非上市股份转换H股，已发行股本增至517,947,790股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634029608","title":"轩竹生物-B(02575)完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2634029608","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634029608?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:32","pubTimestamp":1778574745,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，于2026年5月12日，合共3.57亿股未上市股份已完成转换，而该等转换H股将自2026年5月13日上午九时正起于联交所上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)完成H股全流通","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148901546","title":"轩竹生物-B4月无新增发行 股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1148901546","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148901546?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:56","pubTimestamp":1778144175,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2026年5月7日披露的2026年4月止股份变动月报表显示，公司本月未发生新增发行、股份购回或注销等情况，股本结构保持稳定。截至2026年4月30日，公司 H 股已发行股份数为160,701,996股，与上月持平；未上市股份数量为357,245,794股，与上月相同；两类股份合计517,947,790股，本月公司注册股本及已发行股本总数均未发生变化。本公告由联席公司秘书何成明签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630341907","title":"本土商业化提速叠加海外 BD 突破，轩竹生物-B(02575)拓宽确定性增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2630341907","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630341907?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:21","pubTimestamp":1777335716,"startTime":"0","endTime":"0","summary":"收入同比大增逾70%，“三驾马车”商业化突破在即......2025年轩竹生物-B顺利步入商业化全面起步阶段，进一步巩固了公司的“造血优势”并通过2025年报业绩传达出的跨越盈亏平衡点的预期。2025商业化全面起步，未来两年突破在即近日轩竹生物2025年年度业绩正式出炉。目前来看，轩竹生物在未来2年已显示出强劲的商业化放量预期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":-0.1874},{"period":"3month","weight":-0.477},{"period":"6month","weight":-0.8363},{"period":"1year","weight":-0.0017},{"period":"ytd","weight":-0.8357}],"compareEarnings":[{"period":"1week","weight":0.0318},{"period":"1month","weight":0.1139},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0312},{"period":"1year","weight":0.0613},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}